Vita Health, the first provider of clinically validated suicide prevention through innovative care management announced the close of a $22.5M Series A funding round.
The Vita behavioral health care pathways are based on the founding team’s successful clinical trials published in JAMA, The American Journal of Psychiatry and thousands of patient encounters demonstrating reductions in suicide attempts by more than 60% and deaths by up to 80%.
A group of investors from across the healthcare landscape, including LFE Capital, Athyrium Capital Management, Flare Capital Partners, CVS Health Ventures and CU Healthcare Innovation Fund participated in the round, along with Connecticut Innovations and HopeLab.
Suicide is the second leading cause of death for teens and college age students and a top five killer for adults per the Center for Disease Control and Prevention. In 2021 there were over 1.7 million suicide attempts in the US. Vita Health is the only telehealth provider specialized in suicide care, who also offers teletherapy and psychiatry services for a broad spectrum of behavioral health conditions.
“Our collective motivation was to shift a very deadly curve in our society that has far reaching and lasting implications for all involved,” says Vita Health co-founder and CEO, Lynn Hamilton. “We are humbled by the participation from a broad group of sophisticated, experienced, and strategic investors. With a growing roster of health plan partners, provider partners, employers, colleges and universities, we are expanding our reach to directly address the most challenging mental health problems in the U.S.”
